Wall Street analyst estimates for Novocure Ltd (NVCR): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-10-29 | $-0.23 | ||
| 2026-07-23 | $-0.13 | $-0.33 | +60.8% |
| 2026-04-30 | $-0.62 | $-0.51 | -21.0% |
| 2026-02-26 | $-0.22 | $-0.41 | +46.3% |
| 2025-10-30 | $-0.33 | $-0.42 | +21.4% |
| 2025-07-24 | $-0.36 | $-0.39 | +7.7% |
| 2025-04-24 | $-0.31 | $-0.47 | +34.0% |
| 2025-02-27 | $-0.61 | $-0.34 | -79.4% |
Valuation Ratios
| Price / Book | 5.08 |
| EV / EBITDA | -15.48 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $82.9M | $177.0M | $248.1M | $351.3M | $494.4M | $535.0M | $537.8M | $509.3M | $605.2M | $655.4M |
| Cost of Revenue | $46.3M | $55.6M | $80.0M | $88.6M | $106.5M | $114.9M | $114.9M | $128.3M | $137.2M | $166.9M |
| Gross Profit | $36.6M | $121.4M | $168.0M | $262.7M | $387.9M | $420.2M | $423.0M | $381.1M | $468.0M | $488.5M |
| Research & Development | $41.5M | $38.1M | $50.6M | $79.0M | $132.0M | $201.3M | $206.1M | $223.1M | $209.6M | $224.5M |
| Selling, General & Admin | $110.5M | $122.6M | $151.1M | $184.6M | $225.5M | $263.2M | $306.4M | $390.9M | $428.9M | $417.7M |
| Operating Expenses | $151.9M | $160.7M | $201.7M | $263.6M | $357.5M | $464.5M | $512.5M | $614.7M | $638.5M | $642.3M |
| Operating Income | -$115.3M | -$39.3M | -$33.7M | -$914,000 | $30.4M | -$44.3M | -$89.5M | -$232.9M | -$170.5M | -$153.8M |
| EBITDA | -$108.9M | -$29.1M | -$23.4M | $13.4M | $44.8M | -$38.4M | -$67.9M | -$177.5M | -$109.6M | -$119.0M |
| Interest Expense | $6.9M | $11.7M | $16.9M | $14.6M | $18.1M | $8.8M | $8.1M | $4.9M | $11.7M | 0 |
| Pre-tax Income | -$121.5M | -$48.5M | -$45.9M | -$8.8M | $18.1M | -$52.1M | -$81.8M | -$191.7M | -$131.2M | -$136.2M |
| Income Tax | $10.4M | $13.2M | $17.6M | -$1.6M | -$1.7M | $6.3M | $10.7M | $15.3M | $37.5M | -$23,000 |
| Net Income | -$131.8M | -$61.7M | -$63.6M | -$7.2M | $19.8M | -$58.4M | -$92.5M | -$207.0M | -$168.6M | -$136.2M |
| EPS | $-1.54 | $-0.70 | $-0.69 | $-0.07 | $0.20 | $-0.56 | $-0.88 | $-1.95 | $-1.56 | $-1.22 |
| EPS (Diluted) | $-1.54 | $-0.70 | $-0.69 | $-0.07 | $0.18 | $-0.56 | $-0.88 | $-1.95 | $-1.56 | $-1.22 |
| Shares Outstanding (Diluted) | $85.6M | $88.5M | $91.8M | $97.2M | $108.9M | $103.4M | $104.7M | $106.4M | $107.8M | $111.5M |
Price
| Price | $15.20 |
| Market Cap | $1.8B |
| Exchange | NASDAQ |
| Country | CH |
Related companies: AZTA · BLFS · ESTA · EVO · KMTS · NEOG · PLSE
Explore sector: Healthcare · Medical - Devices
More sections of NVCR: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks